Apatinib, the first angio-genic agent approved by cFDA, is a selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase approved for the treatment of gastric cancer. This evidence concerns the gene KDR and gastric cancer.